Ascelia Pharma

Ascelia Pharma EBIT Growth

The Year-over-Year EBIT Growth of Ascelia Pharma (ACE.ST) as of Nov 5, 2026 is -9.39 %. In the previous year, Year-over-Year EBIT Growth was 38.90 % — a change of -124.14% (lower).

EBIT Growth

-9.39 %

YoY

-124.14%

Last updated:

Year-over-Year EBIT Growth of Ascelia Pharma is 2025 -9.39 % . Year-over-Year EBIT Growth of Ascelia Pharma was 2024 38.90 % . It decreases by -124.14% lower compared to the previous year.

The Ascelia Pharma EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2018
-51.30 SEK
Jan 1, 2019
1.73 SEK
Jan 1, 2020
-154.27 SEK
Jan 1, 2021
-47.65 SEK
Jan 1, 2022
-6.57 SEK
Jan 1, 2023
24.55 SEK
Jan 1, 2024
38.90 SEK
Jan 1, 2025
-9.39 SEK
The Ascelia Pharma EBIT Growth history
YEAREBIT GrowthYoY
-9.39 %-124.14%
38.90 %+58.45%
24.55 %-473.87%
-6.57 %-86.22%
-47.65 %-69.11%
-154.27 %-9,001.80%
1.73 %-103.38%
-51.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ascelia Pharma Stock analysis

What does Ascelia Pharma do? Ascelia Pharma AB develops pharmaceutical products for cancer treatment, focusing on underappreciated drug candidates. The company's pipeline includes Mangoral, a medical imaging drug for liver MRI in patients with impaired kidneys, which has completed phase II clinical trials, and Oncoral, a tablet formulation of irinotecan for gastric cancer treatment, currently in phase I development. Ascelia generates revenue through the development and potential commercialization of these drug candidates, targeting oncology markets with unmet medical needs. The firm identifies and acquires derisked investigational drug candidates, aiming to make them available to cancer patients. Mangoral addresses liver metastases detection in impaired kidney patients, while Oncoral targets gastric cancer treatment. Ascelia's business model relies on advancing these candidates through clinical trials to secure partnerships or regulatory approvals for market entry. Ascelia Pharma AB is headquartered in Malmö, Skåne, and employs 24 full-time staff. The company went public via IPO on March 13, 2019. Its revenue model centers on progressing its pipeline to attract potential partners or buyers for its drug candidates, with no mention of current sales or external funding sources beyond the IPO. Ascelia Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ascelia Pharma stock

Year-over-Year EBIT Growth of Ascelia Pharma is -9.39 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Ascelia Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Ascelia Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Ascelia Pharma

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Ascelia Pharma